Loading...
XTSEMDP
Market cap52mUSD
Dec 23, Last price  
3.05CAD
1D
8.16%
1Q
17.31%
Jan 2017
-32.22%
IPO
-61.64%
Name

Pediapharm Inc

Chart & Performance

D1W1MN
XTSE:MDP chart
P/E
—
P/S
0.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.81%
Rev. gr., 5y
34.84%
Revenues
113m
+4.59%
003,068,6833,692,8342,889,1524,654,4937,750,57225,362,51352,431,95679,660,00076,701,000108,096,000113,054,000
Net income
-214k
L
00-4,998,949000000-28,264,000-2,879,0001,221,000-214,000
CFO
19m
P
00-4,543,2330000005,038,000-1,180,000-1,444,00018,714,000

Profile

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
URL
https://www.medexus.com/en_US
IPO date
Mar 03, 2012
Employees
98
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
113,054
4.59%
108,096
40.93%
76,701
-3.71%
Cost of revenue
100,016
99,254
88,679
Unusual Expense (Income)
NOPBT
13,038
8,842
(11,978)
NOPBT Margin
11.53%
8.18%
Operating Taxes
320
(6,262)
(941)
Tax Rate
2.45%
NOPAT
12,718
15,104
(11,037)
Net income
(214)
-117.53%
1,221
-142.41%
(2,879)
-89.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,606
BB yield
-21.01%
Debt
Debt current
15,743
42,706
15,046
Long-term debt
34,632
28,185
40,795
Deferred revenue
Other long-term liabilities
25,028
28,008
31,988
Net debt
45,120
67,021
45,823
Cash flow
Cash from operating activities
18,714
(1,444)
(1,180)
CAPEX
(50)
(362)
(7,714)
Cash from investing activities
(3,478)
(1,721)
(8,196)
Cash from financing activities
(23,048)
6,405
663
FCF
1,500
12,668
(9,646)
Balance
Cash
5,255
13,069
10,018
Long term investments
(9,198)
Excess cash
6,183
Stockholders' equity
18,318
11,141
7,408
Invested Capital
105,247
119,356
98,432
ROIC
11.32%
13.87%
ROCE
12.39%
7.41%
EV
Common stock shares outstanding
22,487
20,524
19,856
Price
1.61
0.63%
1.60
-49.04%
3.14
-60.25%
Market cap
36,204
10.25%
32,838
-47.33%
62,347
-48.07%
EV
81,324
99,859
108,170
EBITDA
18,844
14,923
(5,833)
EV/EBITDA
4.32
6.69
Interest
13,364
13,606
12,223
Interest/NOPBT
102.50%
153.88%